Intravacc

Executive Summary

Intravacc is a Netherlands-based biotechnology company and specialized Contract Development and Manufacturing Organization (CDMO) with decades of experience in vaccine development. The company offers end-to-end services for external vaccine candidates, from discovery through Phase II clinical trials, leveraging its proprietary technology platforms and analytical expertise. Intravacc serves partners across infectious diseases, oncology, and other therapeutic areas, positioning itself as a key enabler in the vaccine development ecosystem. Its business model is centered on accelerating clients' vaccine programs while generating recurring revenue through service fees and milestones. As a private company at the Phase 1/2 stage, Intravacc is well-positioned to benefit from the growing demand for outsourced vaccine development and manufacturing, particularly in the post-pandemic landscape. The company's focus on niche platforms and long-standing industry relationships provides a competitive moat, though its lack of publicly disclosed pipeline assets or financials makes it challenging to assess valuation. Management's ability to secure high-value contracts and expand capacity will be critical to near-term growth.

Upcoming Catalysts (preview)

• Q3 2026Announcement of Major CDMO Partnership70% success
• Q4 2026Initiation of Phase II Trial for Partnered Vaccine Candidate50% success
• Q1 2027Expansion of Manufacturing Facility or Technology Platform60% success